New 3(2H)-pyridazinone derivatives containing a N'-benzyliden-acetohydrazide moiety at position 2 were synthesized. The structures of these newly synthesized compounds were confi rmed by IR, 1 H NMR, and MS data. These compounds were tested for their antibacterial, antifungal, antimycobacterial, and cytotoxic activities. The compounds 2-[4-(4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-tert-butylbenzyliden)acetohydrazide and 2-[4-(4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-chlorobenzyliden) acetohydrazide exhibited activity against both Gram-positive and Gram-negative bacteria. Most of the compounds were active against E. coli ATCC 35218. The preliminary results of this study revealed that some target compounds exhibited promising antimicrobial activities.
Introduction
For several years the emergence of multidrugresistant bacteria and also -resistant fungi has been reported worldwide. Rapid development of multidrug-resistant microbial pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant S. aureus (VRSA), and vancomycin-resistant Enterococci (VRE) and the lack of effective treatments have made the treatment of infectious diseases as escalating problem (He et al., 2003; Aksoy and Unal, 2008) . Fungal infections are not limited to superfi cial tissues; in fact, advanced age, major surgery, immunosuppressive therapy, acquired immunodefi ciency syndrome (AIDS), cancer treatment, and solid-organ and hema topoietic stem cell transplantation increase the risk of life-threatening systemic fungal infections (Sundriyal et al., 2006) . Therefore novel effective antimicrobial drugs are urgently required.
Pyridazinone derivatives have been reported to exhibit diverse pharmacological activities such as vasodilatory (Bansal et al., 2009) , antihypertensive (Demirayak et al., 2004; Siddiqui et al., 2010) , antiplatelet (Cherng et al., 2006) , analgesic and antiinfl ammatory (Gokce et al., 2009) , anticonvulsant (Rubat et al., 1990) , antibacterial (Longo et al., 1993; Sönmez et al., 2006; Dogruer et al., 2008) , anti-HIV (Livermone et al., 1993) , and anticancer (Malinka et al., 2004) . Previously, we reported the analgesic and anti-infl ammatory activity of novel series of 3(2H)-pyridazinones (Sukuroglu et al., 2006; Dogruer et al., 2003) . Also, pyridazinones offer a valuable ring system to researchers because of easy functionalization at various ring positions. Also, N-acylhydrazone (NAH) compounds have been pointed out as promising antibacterial, antifungal (Suresh Kumar et al., 2010; Mallikarjuna et al., 2009) , antimycobacterial (Sriram et al., 2006) , and antioxidant (Liu et al., 2009) agents. Based on all above mentioned considerations and our interest in chemical and pharmacological properties of pyridazinones, we hereby report the synthesis and biological activities of novel 3(2H)-pyridazinones containing the N'-benzyliden-acetohydrazide moiety.
Material and Methods

Chemistry
Melting points were measured on an SMP-II digital melting point apparatus (Schorpp Geräte technik, Überlingen, Germany). Infrared (IR) spectra were recorded on a Perkin Elmer All chemicals used for the synthesis of the compounds were purchased from Aldrich Chemicals (Sigma-Aldrich, Steinheim, Germany) and Merck (Darmstadt, Germany). The 1 H NMR spectra were recorded on a Varian Mercury 300 FT-NMR spectrometer (Varian Inc., Palo Alto, CA, USA). Chemical shifts (δ) are reported in parts per million (ppm) downfi eld from tetramethylsilane (TMS) as internal standard. DMSO-d 6 was used as solvent. High-resolution mass spectroscopy (HRMS) was done on a Micromass LCT Premier XE mass spectrometer (Waters, Milford, MA, USA) using an electrospray ion (ESI) source.
Synthesis and in vitro
Synthesis of compounds 1 and 2 was accomplished according to the previously reported procedures (Sukuroglu et al., 2006) . Compounds 3a, 3b, and 4a -4r were prepared for the fi rst time in this study.
Synthesis of 2-[4-(phenyl/4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-acetohydrazide (3a, 3b)
Ethyl 2-[4-(phenyl/4-chlorophenyl)-6-(mor pholin -4-yl)-3-oxo-(2H)-pyridazin-2-yl] acetate (2a, 2b) (0.01 mol) was refl uxed with hydrazine hydrate (0.02 mol) in ethanol (20 mL) for 4 h. At the end of the period, the reaction mixture was cooled. The precipitate was fi ltered, dried, and crystallized from methanol. 2-[4-(phenyl/4-chlorophenyl)-6-(morpholin-4-yl 
Synthesis of
) (0.01 mol), appropriate benzaldehyde derivatives (0.011 mol), and acetic acid (1 -2 drops) were heated at refl ux in ethanol for 3 h. The precipitated compound was fi ltered. The residue was washed with hot ethanol and dried. (CLSI, 2006 ). All organisms were tested in triplicate in each run of the experiments.
2-
2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-methoxybenzyliden)acetohydrazide
2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-eth oxy benzy li den) -
2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-chlorobenzyliden)-
2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-fl uorobenzyliden)-
2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-trifluoromethylbenzyliden)acetohydrazide
2-[4-(4-Chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(2-fl uorobenzyliden)-
2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-benzyliden-acetohydrazide
2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-methylbenzyliden)aceto-
2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-methoxybenzyliden
2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-ethoxybenzyliden
2-[4-Phenyl-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-N'-(4-chlorobenzyliden
All bacterial isolates were subcultured on Mueller-Hinton agar (MHA; Merck) and incubated overnight at 37 °C. The stock solutions of the newly synthesized compounds and standard drugs were diluted with liquid medium stepwise by half from 2048 down to 0.0625 µg/mL in the wells of microplates. The bacterial susceptibility test was performed according to the guidelines of CLSI M100-S18 (CLSI, 2008a). The bacterial suspensions used for inoculation were prepared at 10 5 CFU/mL by diluting fresh cultures at a McFarland density of 0.5 (10 7 CFU/mL), and the wells were inoculated at 10 4 CFU/mL. MuellerHinton broth (MHB; Merck) was used for all dilutions. Dimethyl sulfoxide (DMSO; Sigma Aldrich, Poole, UK), phosphate-buffered saline (PBS), pure microorganisms, and pure media were used in control wells. A 10-µL bacterial inoculum was added to each well. The trays were incubated at 37 °C, and minimum inhibitory concentration (MIC) endpoints were read after 24 h of incubation.
Antifungal assay
The newly synthesized compounds were evaluated for their antifungal activity against Candida albicans ATCC 10231 and Candida krusei ATCC 6258. All organisms were tested in triplicate in each run of the experiments.
Candida was subcultured on Sabouraud dextrose agar (SDA; Merck) and incubated at 35 °C for 24 -48 h. Susceptibility testing was performed in RPMI-1640 medium supplemented with L-glutamine (Sigma) and buffered with 3-(N-morpholino)propanesulfonic acid (MOPS, pH 7; Sigma), and culture suspensions were prepared according to the guideline of CLSI M27-A3 (CLSI, 2008b) . Yeast suspensions were prepared at a McFarland density of 0.5, and a working suspension was prepared by 1:100 dilution followed by 1:20 dilution of the stock suspension (2.5·10 3 CFU/mL). A 10-µL yeast inoculum was added to each well of the microdilution trays. The trays were incubated at 35 °C, and MIC endpoints were read after 48 h of incubation.
Antimycobacterial assay
The in vitro activity of the synthesized compounds against Mycobacterium tuberculosis H37RV ATCC 27294 was determined by the microplate alamar blue assay (MABA) (Franzblau et al., 1998 ). All organisms were tested in triplicate in each run of the experiments.
Mycobacterium tuberculosis H37RV ATCC 27294 was subcultured on Middlebrook 7H11 agar (Becton Dickinson, Franklin Lakes, NJ, USA). Culture suspensions were prepared in 0.04% (v/v) Tween 80/0.2% bovine serum albumin (Sigma) at a McFarland density of 1. Suspensions were then diluted 1:25 in 7H9GC broth (Difco, Le Pont de Claix, France), 20 mL of 10% (v/v) glycerol, 1 g of Bacto Casitone (Difco), 880 mL of distilled water, and 100 mL of Middlebrook OADC Growth Supplement (Sigma). The stock solutions of the newly synthesized compounds and standard drugs were diluted with liquid medium stepwise by half from 2048 down to 0.0625 µg/mL in the wells of microplates in the liquid media. The plates were sealed with parafi lm and incubated at 37 °C for 5 d. Fif-ty µL of a freshly prepared 1:1 mixture of 10X alamar blue (AbD Serotec, Oxford, UK) reagent and 10% Tween 80 were added to the control well. The plates were incubated at 37 °C for 24 h. The control well turned pink, and the reagent mixture was added to all wells in the microplate. The microplates were resealed with parafi lm and incubated for 24 h at 37 °C, and the colours of all wells were recorded. A blue colour in the well was scored as no growth and a pink colour as growth, respectively. The MIC was defi ned as the lowest drug concentration which prevented a colour change from blue to pink.
Cytotoxicity assay
The level of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma) reduction was quantifi ed as previously described in the literature with small modifi cations (Mossmann, 1983; Keiser et al., 2000) .
Cell culture and drug treatment NIH/3T3 cells were obtained from the American Type Culture Collection (ATCC, CRL-1658). The cells were incubated in Dulbecco's modifi ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum (Gibco, Paisley, Scotland), 100 IU/mL penicillin (Gibco), and 100 mg/mL streptomycin (Gibco) at 37 °C in a humidifi ed atmosphere of 95% air and 5% CO 2 . Exponentially growing cells were plated at 2 · 10 4 cells/mL into 96-well microtiter tissue culture plates (Nunc, Roskilde, Denmark) and incubated for 24 h and 48 h before the addition of the drugs (the optimum cell number for cytotoxicity assays was determined in preliminary experiments). Stock solutions of compounds were prepared in DMSO (Sigma Aldrich), and further dilutions were made with fresh culture medium (the content of DMSO in the fi nal culture medium was <0.1% which had no effect on cell viability).
MTT assay for cytotoxicity tests of the compounds
After 24 h or 48 h of preincubation, the synthetized compounds were added to give fi nal concentrations in the range 0.5 -512 µM, and the cells were incubated for 24 h. At the end of this period, MTT was added to a fi nal concentration of 0.5 mg/ mL, and the cells were incubated for 4 h at 37 °C. After the medium was removed, the formazan crystals formed were solubilized by addition of 200 mL DMSO to each well, and absorbance was read at 540 nm with a microtitre plate spectrophotometer (Bio-Tek plate reader; Winooski, VT, USA). Every concentration was repeated in three wells, and IC 50 values were defi ned as the drug concentrations that reduced absorbance to 50% of control values.
Results and Discussion
We synthesized twenty new compounds, the synthetic route of which is outlined in Scheme 1. Procedures for the synthesis of compounds 1a, 1b and 2a, 2b have been reported by us in our previous study (Sukuroglu et al., 2006) . Compounds 3a, 3b and 4a -4r were prepared for the fi rst time in this study. 2-[4-(Phenyl/4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl]-acetohydrazide (3a, 3b) was obtained by the reaction of ethyl 2-[4-(phenyl/4-chlorophenyl)-6-(morpholin-4-yl)-3-oxo-(2H)-pyridazin-2-yl] aceta te with hydrazine hydrate in ethanol. The new compounds 4a -4r were synthesized, in good yields, by condensing compounds 3a and 3b with the respective aromatic aldehydes in ethanol (Table I) .
The structures of these stable and crystalline compounds were fully characterized by the usual methods (IR, 1 H NMR). In the IR spectra, N-H, C=O (acylhydrazone), and C=O (pyridazinone ring) peaks were seen at 3208 -3183 cm -1 , 1764 -1676 cm -1 , and 1671 -1642 cm -1 , respectively. In the 1 H NMR spectra of these compounds, signals due to N=CH and -CH 2 CO-groups appeared as two separate singlets. It is well known that N-acylhydrazones may exist as two geometrical isomers, E/Z. On the other hand, the reason for the existence of two different singlets of the -CH 2 CO-group may be due to two rotamers. This is, because the N-H group may form a hydrogen bond with the ring carbonyl group and thus form a pseudoring, which restricts the rotation. This suggestion may also be supported by the relative weakness of the ring carbonyl group peak in the IR spectra of the compounds (CLSI, 2006; CLSI, 2008b) . High-resolution mass spectra confi rmed the molecular masses and empirical formulas of compounds 3a, 3b, and 4a -4r, with less than 5 ppm bias between calculated and experimental m/z values of the molecular ions.
The synthesized 3(2H)-pyridazinone derivatives 3a, 3b, and 4a -4r were screened for their antibacterial, antifungal, and antimycobacterial activities. Twelve strains were used as test micro-organisms including ten bacterial and two fungal species, respectively. Ampicillin, gentamicin, amoxicillin, clavulanic acid, fl uconazole, and amphotericin B for antibacterial activity, and ethambutol for antimycobacterial activity were used as reference drugs. The minimal inhibitory concentration (MIC) values of the 3(2H)-pyridazinone derivatives are reported in Table II and Table III along with those of the standard drugs. The results revealed that the majority of the synthesized compounds 3a, 3b, 4e, 4f, 4i, 4j, 4k, 4l, 4 m, 4n, 4p , and 4r exhibited antibacterial activity at 64 µg/mL against E. coli ATCC 35218. Among the synthesized compounds 4e, having an MIC value of 8 µg/ mL, was found to be the most active derivative against the Gram-positive bacterium E. faecalis ATCC 29212. Compounds 4c, 4f, and 4q had lower MIC values (64 µg/mL) than compounds 4a, 4b, 4h, 4i, 4o, and 4p (128 µg/mL) against E. faecalis ATCC 29212. Furthermore, the compounds were inactive against P. aeruginosa ATCC 27853. The results given in Table II indicate that among the new compounds tested, only compound 4h showed a somewhat higher antifungal activity against C. albicans ATCC 10231 than the others.
In comparison to their antibacterial activity, none of the compounds had promising antifungal activity against C. albicans and C. krusei. The acylhydrazones 4a -4r inhibited M. tuberculosis with MIC values ranging from 256 to 512 µg/mL, and were less effective than the reference drug (Table III) .
In general, the inhibitory activities of the compounds tested against the Gram-negative bacteria were higher than those against the Gram-positive bacteria. Compounds 4c, 4f, and 4q exhibited both Gram-positive and Gram-negative antibacterial activity. Therefore, one can state that the presence of electron-donating or -withdrawing properties, respectively, of the groups on the phenyl ring at the side chain do not play a crucial role in the activity of the synthesized compounds.
Cytotoxic effects of the most active compounds were evaluated as well. The toxicity of all studied compounds increased in a dose-dependent manner, compounds 4e and 4q being the most toxic ones. Also, toxicity of 4q increased with increasing incubation time. But toxicity of the other compounds decreased with increasing incubation time and their IC 50 values were higher (Table IV) .
In conclusion, a series of new 3(2H)-pyridazinone derivatives, 3a, 3b, and 4a -4r, were synthesized in an effort to obtain new antimicrobial agents. All compounds were examined for their in vitro antimicrobial and antimycobacterial activities. The results of the preliminary activity tests of this class of compounds might lead to the development of better candidates with potent antimicrobial activities.
